PRESS RELEASE published on 02/10/2026 at 07:30, 3 months 3 days ago Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Nicox to present NCX 470 Phase 3 data at AGS Annual Meeting 2026 with podium presentations showcasing clinical study results and efficacy of the ophthalmic solution Clinical Study Ophthalmology Nicox NCX 470 AGS Annual Meeting 2026
BRIEF published on 01/20/2026 at 07:35, 3 months 24 days ago Nicox announces its participation in several congresses in 2026 Glaucoma Ophthalmology Nicox NCX 470 Congress 2026
BRIEF published on 01/20/2026 at 07:35, 3 months 24 days ago Nicox Announces 2026 Conference Participation and Data Presentations Scientific Data Ophthalmology NCX 470 Conference Participation 2026 Events
PRESS RELEASE published on 01/20/2026 at 07:30, 3 months 24 days ago Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations Nicox to attend key ophthalmology conferences and present scientific data at AGS 2026 Annual Meeting. Management team available for meetings. Developing innovative eye health solutions Conference Scientific Data Ophthalmology Nicox Eye Health
BRIEF published on 12/16/2025 at 07:35, 4 months 28 days ago Nicox Finalizes Key Data for NCX 470 NDA Submission by H1 2026 Clinical Trials Ophthalmology Nicox NCX 470 NDA Submission
PRESS RELEASE published on 12/16/2025 at 07:30, 4 months 28 days ago Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Nicox completes key data generation for NCX 470 new drug application submission in H1 2026, including clinical trial and stability data. U.S. and China submissions on track FDA Clinical Trials Nicox NCX 470 New Drug Application
BRIEF published on 10/23/2025 at 07:35, 6 months 21 days ago Nicox Releases First Half 2025 Financial Results Financial Results Debt Repayment Ophthalmology Cost Control NCX 470
PRESS RELEASE published on 10/23/2025 at 07:30, 6 months 21 days ago Nicox Provides First Half 2025 Financial Results Nicox provides first half 2025 financial results, expects NDA submissions for NCX 470 in 2026. Company aims to finance operations for 12 months and repay debts by 2026 Financial Results Debt Repayment Nicox NCX 470 NDA Submissions
BRIEF published on 10/02/2025 at 07:35, 7 months 11 days ago Nicox: Positive results for NCX 470 in the Denali study Clinical Trial Ophthalmology Nicox NCX 470 Intraocular Pressure
PRESS RELEASE published on 10/02/2025 at 07:30, 7 months 11 days ago Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Nicox's NCX 470 shows sustained efficacy with no new safety concerns in Denali trial. Data presented at upcoming ophthalmology conferences Nicox NCX 470 Denali Trial Ophthalmology Conferences Sustained Efficacy
Published on 05/13/2026 at 23:30, 26 minutes ago CCL Industries Announces Results for 2026 First Quarter
Published on 05/13/2026 at 23:05, 51 minutes ago Vox Royalty Reports Record Q1 2026 Results, Increases 2026 Guidance and Declares Quarterly Dividend
Published on 05/13/2026 at 22:30, 1 hour 26 minutes ago Amdocs Entitlement Server Sets New Industry Performance Benchmark on Microsoft Azure
Published on 05/13/2026 at 22:25, 1 hour 31 minutes ago Lumen Technologies Accelerates Cloud-First Strategy with Amdocs, Expands Migration of Enterprise Billing Platform to Microsoft Azure
Published on 05/13/2026 at 22:20, 1 hour 35 minutes ago Rumble Announces Initial Results of Exchange Offer for Northern Data
Published on 05/13/2026 at 20:18, 3 hours 37 minutes ago EQS-Adhoc: Northern Data Group Q1 2026 – Above the Preliminary Ranges Communicated on 8 April 2026
Published on 05/13/2026 at 19:28, 4 hours 27 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/13/2026 at 19:14, 4 hours 41 minutes ago EQS-Adhoc: Oldenburgische Landesbank AG: Oldenburgische Landesbank AG intends to call its Additional Tier 1 bond
Published on 05/13/2026 at 17:45, 6 hours 11 minutes ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
Published on 05/13/2026 at 17:45, 6 hours 11 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
Published on 05/13/2026 at 17:40, 6 hours 16 minutes ago Report on share repurchases from 6 to 12 May 2026
Published on 05/13/2026 at 16:00, 7 hours 56 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
